|
1
|
Torre LA, Islami F, Siegel RL, Ward EM and
Jemal A: Global cancer in women: Burden and trends. Cancer
Epidemiol Biomarkers Prev. 26:444–457. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Burstein HJ: The distinctive nature of
HER2-positive breast cancers. N Engl J Med. 353:1652–1654. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kennecke H, Yerushalmi R, Woods R, Cheang
MC, Voduc D, Speers CH, Nielsen TO and Gelmon K: Metastatic
behavior of breast cancer subtypes. J Clin Oncol. 28:3271–3277.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Harbeck N, Penault-Llorca F, Cortes J,
Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J and Cardoso F:
Breast cancer. Nat Rev Dis Primers. 5:662019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iqbal N and Iqbal N: Human epidermal
growth factor receptor 2 (HER2) in cancers: Overexpression and
therapeutic implications. Mol Biol Int. 2014:8527482014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mendes D, Alves C, Afonso N, Cardoso F,
Passos-Coelho JL, Costa L, Andrade S and Batel-Marques F: The
benefit of HER2-targeted therapies on overall survival of patients
with metastatic HER2-positive breast cancer - a systematic review.
Breast Cancer Res. 17:1402015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hudis CA: Trastuzumab - mechanism of
action and use in clinical practice. N Engl J Med. 357:39–51. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vogel CL, Cobleigh MA, Tripathy D, Gutheil
JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF,
Burchmore M, et al: Efficacy and safety of trastuzumab as a single
agent in first-line treatment of HER2-overexpressing metastatic
breast cancer. J Clin Oncol. 20:719–726. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
et al: Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Andersson M, Lidbrink E, Bjerre K, Wist E,
Enevoldsen K, Jensen AB, Karlsson P, Tange UB, Sørensen PG, Møller
S, et al: Phase III randomized study comparing docetaxel plus
trastuzumab with vinorelbine plus trastuzumab as first-line therapy
of metastatic or locally advanced human epidermal growth factor
receptor 2-positive breast cancer: The HERNATA study. J Clin Oncol.
29:264–271. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Robert N, Leyland-Jones B, Asmar L, Belt
R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M,
et al: Randomized phase III study of trastuzumab, paclitaxel, and
carboplatin compared with trastuzumab and paclitaxel in women with
HER-2-overexpressing metastatic breast cancer. J Clin Oncol.
24:2786–2792. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Valero V, Forbes J, Pegram MD, Pienkowski
T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crown J, Mackey
JR, et al: Multicenter phase III randomized trial comparing
docetaxel and trastuzumab with docetaxel, carboplatin, and
trastuzumab as first-line chemotherapy for patients with
HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): Two
highly active therapeutic regimens. J Clin Oncol. 29:149–156. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baselga J, Manikhas A, Cortés J, Llombart
A, Roman L, SemiglazovV F, Byakhov M, Lokanatha D, Forenza S,
Goldfarb RH, et al: Phase III trial of nonpegylated liposomal
doxorubicin in combination with trastuzumab and paclitaxel in
HER2-positive metastatic breast cancer. Ann Oncol. 25:592–598.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hamberg P, Bos MM, Braun HJ, Stouthard JM,
van Deijk GA, Erdkamp FL, van der Stelt-Frissen IN, Bontenbal M,
Creemers GJ, Portielje JE, et al Dutch Breast Cancer Trialists'
Group (BOOG), : Randomized phase II study comparing efficacy and
safety of combination-therapy trastuzumab and docetaxel vs.
sequential therapy of trastuzumab followed by docetaxel alone at
progression as first-line chemotherapy in patients with HER2+
metastatic breast cancer: HERTAX trial. Clin Breast Cancer.
11:103–113. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Inoue K, Nakagami K, Mizutani M, Hozumi Y,
Fujiwara Y, Masuda N, Tsukamoto F, Saito M, Miura S, Eguchi K, et
al: Randomized phase III trial of trastuzumab monotherapy followed
by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as
first-line therapy in patients with HER2-positive metastatic breast
cancer: The JO17360 Trial Group. Breast Cancer Res Treat.
119:127–136. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pagani O, Klingbiel D, Ruhstaller T, Nolè
F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D,
Mamot C, et al Swiss Group for Clinical Cancer Research (SAKK), :
Do all patients with advanced HER2 positive breast cancer need
upfront-chemo when receiving trastuzumab? Randomized III trial SAKK
22/99. Ann Oncol. 28:305–312. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Baselga J, Cortés J, Kim SB, Im SA, Hegg
R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, et al
CLEOPATRA Study Group, : Pertuzumab plus trastuzumab plus docetaxel
for metastatic breast cancer. N Engl J Med. 366:109–119. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Swain SM, Baselga J, Kim S-B, Ro J,
Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A,
Heeson S, et al CLEOPATRA Study Group, : Pertuzumab, trastuzumab,
and docetaxel in HER2-positive metastatic breast cancer. N Engl J
Med. 372:724–734. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Swain SM, Miles D, Kim SB, Im YH, Im SA,
Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, et al:
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic
breast cancer (CLEOPATRA): end-of-study results from a
double-blind, randomised, placebo-controlled, phase 3 study. Lancet
Oncol. 21:519–530. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Miles D, Im YH, Fung A, Yoo B, Knott A,
Heeson S, Beattie MS and Swain SM: Effect of docetaxel duration on
clinical outcomes: Exploratory analysis of CLEOPATRA, a phase III
randomized controlled trial. Ann Oncol. 28:2761–2767. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bachelot T, Ciruelos E, Schneeweiss A,
Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S,
Wardley A, Merot JL, du Toit Y, et al PERUSE investigators, :
Preliminary safety and efficacy of first-line pertuzumab combined
with trastuzumab and taxane therapy for HER2-positive locally
recurrent or metastatic breast cancer (PERUSE). Ann Oncol.
30:766–773. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Perez EA, López-Vega JM, Petit T, Zamagni
C, Easton V, Kamber J, Restuccia E and Andersson M: Safety and
efficacy of vinorelbine in combination with pertuzumab and
trastuzumab for first-line treatment of patients with HER2-positive
locally advanced or metastatic breast cancer: VELVET Cohort 1 final
results. Breast Cancer Res. 18:1262016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Inoue K, Ninomiya J, Saito T, Okubo K,
Nakakuma T, Yamada H, Kimizuka K and Higuchi T; SBCCSG-36
investigators, : Eribulin, trastuzumab, and pertuzumab as
first-line therapy for patients with HER2-positive metastatic
breast cancer: A phase II, multicenter, collaborative, open-label,
single-arm clinical trial. Invest New Drugs. 37:538–547.
2019.Erratum in: Invest New Drugs 37: 592–593, 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Urruticoechea A, Rizwanullah M, Im SA,
Ruiz ACS, Láng I, Tomasello G, Douthwaite H, Badovinac Crnjevic T,
Heeson S, Eng-Wong J, et al: Randomized phase III trial of
trastuzumab plus capecitabine with or without pertuzumab in
patients with human epidermal growth factor receptor 2-positive
metastatic breast cancer who experienced disease progression during
or after trastuzumab-based therapy. J Clin Oncol. 35:3030–3038.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Urruticoechea A, Rizwanullah M, Im SA,
Sánchez Ruiz AC, Lang I, Tomasello G, Douthwaite H, Badovinac
Crnjevic T, Heeson S, Eng-Wong J, et al: Final overall survival
(OS) analysis of PHEREXA: A randomized phase III trial of
trastuzumab (H) + capecitabine (X) ± pertuzumab (P) in patients
with HER2-positive metastatic breast cancer (MBC) who experienced
disease progression during or after H-based therapy. J Clin Oncol.
36 (Suppl 15):10132018. View Article : Google Scholar
|
|
27
|
Lewis Phillips GD, Li G, Dugger DL,
Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV,
Lutz RJ, et al: Targeting HER2-positive breast cancer with
trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res.
68:9280–9290. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Krop IE, Kim SB, González-Martín A,
LoRusso PM, Ferrero JM, Smitt M, Yu R, Leung AC and Wildiers H;
TH3RESA study collaborators, : Trastuzumab emtansine versus
treatment of physician's choice for pretreated HER2-positive
advanced breast cancer (TH3RESA): A randomised, open-label, phase 3
trial. Lancet Oncol. 15:689–699. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Krop IE, Kim SB, Martin AG, LoRusso PM,
Ferrero JM, Badovinac-Crnjevic T, Hoersch S, Smitt M and Wildiers
H: Trastuzumab emtansine versus treatment of physician's choice in
patients with previously treated HER2-positive metastatic breast
cancer (TH3RESA): Final overall survival results from a randomised
open-label phase 3 trial. Lancet Oncol. 18:743–754. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Verma S, Miles D, Gianni L, Krop IE,
Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, et al
EMILIA Study Group, : Trastuzumab emtansine for HER2-positive
advanced breast cancer. N Engl J Med. 367:1783–1791. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Diéras V, Miles D, Verma S, Pegram M,
Welslau M, Baselga J, Krop IE, Blackwell K, Hoersch S, Xu J, et al:
Trastuzumab emtansine versus capecitabine plus lapatinib in
patients with previously treated HER2-positive advanced breast
cancer (EMILIA): A descriptive analysis of final overall survival
results from a randomised, open-label, phase 3 trial. Lancet Oncol.
18:732–742. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Perez EA, Barrios C, Eiermann W, Toi M, Im
YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H III, et al:
Trastuzumab emtansine with or without pertuzumab versus trastuzumab
plus taxane for human epidermal growth factor receptor 2-positive,
advanced breast cancer: Primary results From the Phase III MARIANNE
Study. J Clin Oncol. 35:141–148. 2017.Erratum in: J Clin Oncol 35:
2342, 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Perez EA, Barrios C, Eiermann W, Toi M, Im
YH, Conte P, Martin M, Pienkowski T, Pivot XB, Burris HA III, et
al: Trastuzumab emtansine with or without pertuzumab versus
trastuzumab with taxane for human epidermal growth factor receptor
2-positive advanced breast cancer: Final results from MARIANNE.
Cancer. 125:3974–3984. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Roskoski R Jr: Small molecule inhibitors
targeting the EGFR/ErbB family of protein-tyrosine kinases in human
cancers. Pharmacol Res. 139:395–411. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cameron D, Casey M, Press M, Lindquist D,
Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B,
Crown J, et al: A phase III randomized comparison of lapatinib plus
capecitabine versus capecitabine alone in women with advanced
breast cancer that has progressed on trastuzumab: Updated efficacy
and biomarker analyses. Breast Cancer Res Treat. 112:533–543. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gelmon KA, Boyle FM, Kaufman B, Huntsman
DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Lemieux J,
Aparicio S, et al: Lapatinib or trastuzumab plus taxane therapy for
human epidermal growth factor receptor 2-positive advanced breast
cancer: Final results of NCIC CTG MA.31. J Clin Oncol.
33:1574–1583. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Blackwell KL, Burstein HJ, Storniolo AM,
Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S,
Bischoff J, et al: Overall survival benefit with lapatinib in
combination with trastuzumab for patients with human epidermal
growth factor receptor 2-positive metastatic breast cancer: Final
results from the EGF104900 Study. J Clin Oncol. 30:2585–2592. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Prat A and Baselga J: The role of hormonal
therapy in the management of hormonal-receptor-positive breast
cancer with co-expression of HER2. Nat Clin Pract Oncol. 5:531–542.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Montagna E and Colleoni M: Hormonal
treatment combined with targeted therapies in endocrine-responsive
and HER2-positive metastatic breast cancer. Ther Adv Med Oncol.
11:17588359198941052019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kaufman B, Mackey JR, Clemens MR, Bapsy
PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova
A, et al: Trastuzumab plus anastrozole versus anastrozole alone for
the treatment of postmenopausal women with human epidermal growth
factor receptor 2-positive, hormone receptor-positive metastatic
breast cancer: Results from the randomized phase III TAnDEM study.
J Clin Oncol. 27:5529–5537. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Johnston S, Pippen J Jr, Pivot X,
Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A,
Kennedy MJ, et al: Lapatinib combined with letrozole versus
letrozole and placebo as first-line therapy for postmenopausal
hormone receptor-positive metastatic breast cancer. J Clin Oncol.
27:5538–5546. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Huober J, Fasching PA, Barsoum M,
Petruzelka L, Wallwiener D, Thomssen C, Reimer T, Paepke S, Azim
HA, Ragosch V, et al: Higher efficacy of letrozole in combination
with trastuzumab compared to letrozole monotherapy as first-line
treatment in patients with HER2-positive, hormone-receptor-positive
metastatic breast cancer - results of the eLEcTRA trial. Breast.
21:27–33. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rimawi M, Ferrero J-M, de la
Haba-Rodriguez J, Poole C, De Placido S, Osborne CK, Hegg R, Easton
V, Wohlfarth C and Arpino G; PERTAIN Study Group, : First-line
trastuzumab plus an aromatase inhibitor, with or without
pertuzumab, in human epidermal growth factor receptor 2-positive
and hormone receptor-positive metastatic or locally advanced breast
cancer (PERTAIN): A randomized, open-label phase II trial. J Clin
Oncol. 36:2826–2835. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Johnston SRD, Hegg R, Im SA, Park IH,
Burdaeva O, Kurteva G, Press MF, Tjulandin S, Iwata H, Simon SD, et
al: Phase III, randomized study of dual human epidermal growth
factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab
in combination with an aromatase inhibitor in postmenopausal women
with HER2-positive, hormone receptor-positive metastatic breast
cancer: ALTERNATIVE. J Clin Oncol. 36:741–748. 2018.Retraction in:
J Clin Oncol 39: 95, 2021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Saura C, Oliveira M, Feng Y, Dai M-S,
Hurvitz SA, Kim SB, Moy B, Delaloge S, Gradishar WJ, Masuda N, et
al: Neratinib plus capecitabine versus lapatinib plus capecitabine
in HER2-positive metastatic breast cancer previously treated with
≥2 HER2-directed regimens: Phase III NALA trial. J Clin Oncol.
38:3138–3149. 2019. View Article : Google Scholar
|
|
46
|
Awada A, Colomer R, Inoue K, Bondarenko I,
Badwe RA, Demetriou G, Lee SC, Mehta AO, Kim SB, Bachelot T, et al:
Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in
previously untreated metastatic ERBB2-positive breast cancer. The
NEfERT-T randomized clinical trial. JAMA Oncol. 2:1557–1564. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Freedman RA, Gelman RS, Wefel JS, Melisko
ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL,
Ibrahim N, et al: Translational Breast Cancer Research Consortium
(TBCRC) 022: A phase II trial of neratinib for patients with human
epidermal growth factor receptor 2-positive breast cancer and brain
metastases. J Clin Oncol. 34:945–952. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Freedman RA, Gelman RS, Anders CK, Melisko
ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP,
Marte JM, et al Translational Breast Cancer Research Consortium, :
TBCRC 022: A phase II trial of neratinib and capecitabine for
patients with human epidermal growth factor receptor 2-positive
breast cancer and brain metastases. J Clin Oncol. 37:1081–1089.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ma F, Ouyang Q, Li W, Jiang Z, Tong Z, Liu
Y, Li H, Yu S, Feng J, Wang S, et al: Pyrotinib or lapatinib
combined with capecitabine in HER2-positive metastatic breast
cancer with prior taxanes, anthracyclines, and/or trastuzumab: A
randomized, phase II study. J Clin Oncol. 37:2610–2619. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Xu B, Yan M, Ma F, Hu XC, Feng FJ, Ouyang
Q, Tong Z, Li H, Zhang Q, Sun T, et al: Pyrotinib or lapatinib plus
capecitabine for HER2+ metastatic breast cancer (PHOEBE): a
randomized phase III trial. J Clin Oncol. 38 (Suppl 15):10032020.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Jiang Z, Yan M, Hu X, Zhang Q, Ouyang Q,
Feng J, Yin Y, Sun T, Tong Z, Wang X, et al: Pyrotinib combined
with capecitabine in women with HER2+ metastatic breast cancer
previously treated with trastuzumab and taxanes: A randomized phase
III study. J Clin Oncol. 37 (Suppl 15):10012019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Blair HA: Pyrotinib: First global
approval. Drugs. 78:1751–1755. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Murthy RK, Loi S, Okines A, Paplomata E,
Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, et
al: Tucatinib, trastuzumab and capecitabine for HER2-positive
metastatic breast cancer. N Engl J Med. 382:597–609. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lin NU, Borges V, Anders C, Murthy RK,
Paplomata E, Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, et
al: Intracranial efficacy and survival with tucatinib plus
trastuzumab and capecitabine for previously treated HER2-positive
breast cancer with brain metastases in the HER2CLIMB trial. J Clin
Oncol. 38:2610–2619. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Modi S, Saura C, Yamashita T, Park YH, Kim
SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, et al
DESTINY-Breast01 Investigators, : Trastuzumab Deruxtecan in
previously treated HER2-positive breast cancer. N Engl J Med.
382:610–621. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Jerusalem G, Park YH, Yamashita T, Hurvitz
SA, Chen S, Cathcart J, Lee C and Perrin C: CNS metastases in
HER2-positive metastatic breast cancer treated with trastuzumab
deruxtecan: DESTINY-Breast01 subgroup analyses. Ann Oncol.
31:Abstract nr. 1380. 2020. View Article : Google Scholar
|
|
57
|
Banerji U, van Herpen CML, Saura C,
Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C,
de Vries EGE, et al: Trastuzumab duocarmazine in locally advanced
and metastatic solid tumours and HER2-expressing breast cancer: A
phase 1 dose-escalation and dose-expansion study. Lancet Oncol.
20:1124–1135. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Rinnerthaler G, Gampenrieder SP and Greil
R: HER2 directed antibody-drug-conjugates beyond T-DM1 in breast
cancer. Int J Mol Sci. 20:1152019. View Article : Google Scholar
|
|
59
|
Dolcetti R: Predictive value of FcR
polymorphisms. A further step on the long and winding road to
application. JAMA Oncol. 3:342–343. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Rugo HS, Im SA, Cardoso F, Cortes J,
Curigliano G, Pegram MD, Musolino A, Bachelot T, Wright GS, De
Laurentiis M, et al: Phase III SOPHIA study of margetuximab +
chemotherapy vs trastuzumab + chemotherapy in patients with HER2+
metastatic breast cancer after prior anti-HER2 therapies: second
interim overall survival analysis. Cancer Res. 80:Abstract Nr.
GS1-02. 2019.
|
|
61
|
Meric-Bernstam F, Hanna D, Beeram M, Lee
K, Kang Y, Chaves J, Lee J, Goodwin R, Vaklavas C, Oh D, et al:
Safety, anti-tumor activity, and biomarker results of the
HER2-targeted bispecific antibody ZW25 in HER2-expressing solid
tumors. Ann Oncol. 30 (Suppl 5):v159–v193. 2019. View Article : Google Scholar
|
|
62
|
Alsina M, Boni V, Schellens J, Moreno V,
Bol K, Westendorp M, Sirulnik LA, Tabernero J and Calvo E:
First-in-human phase 1/2 study of MCLA-128, a full length IgG1
bispecific antibody targeting HER2 and HER3: Final phase 1 data and
preliminary activity in HER2+ metastatic breast cancer (MBC). J
Clin Oncol. 35 (Suppl 15):25222017. View Article : Google Scholar
|
|
63
|
Schettini F, Giudici F, Giuliano M,
Cristofanilli M, Arpino G, Del Mastro L, Puglisi F, De Placido S,
Paris I, De Placido P, et al: Overal survival of
CDK4/6-inhibitors-based treatments in clinically relevant subgroups
of metastatic breast cancer: Systematic review and meta-analysis. J
Natl Cancer Inst. 112:1089–1097. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Tolaney SM, Wardley AM, Zambelli S, Hilton
JF, Troso-Sandoval TA, Ricci F, Im SA, Kim SB, Johnston SR, Chan A,
et al: Abemaciclib plus trastuzumab with or without fulvestrant
versus trastuzumab plus standard-of-care chemotherapy in women with
hormone receptor-positive, HER2-positive advanced breast cancer
(monarcHER): A randomised, open-label, phase 2 trial. Lancet Oncol.
21:763–775. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Ciruelos E, Villagrasa P, Paré L, Oliveira
M, Pernas S, Cortés J, Soberino J, Adamo B, Vazquez S, Martínez N,
et al: SOLTI-1303 PATRICIA phase II trial (STAGE 1) - Palbociclib
and trastuzumab in postmenopausal patients with HER2-positive
metastatic breast cancer. Cancer Res. 79 (Suppl 4):Abstract nr
PD3-03. 2019.
|
|
66
|
Metzger O, Mandrekar S, Loibl S, Mundhenke
C, Seiler S, Valagussa P, Lim E, Tripathy D, Winer EP, Huang C, et
al: PATINA: A randomized, open label, phase III trial to evaluate
the efficacy and safety of palbociclib + anti-HER2 therapy +
endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction
treatment for hormone receptor positive (HR+)/HER2-positive
metastatic breast cancer (MBC). Cancer Res. 79 (Suppl 4):Abstract
nr OT3-02-07. 2019.
|
|
67
|
Wang Q, Liu P, Spangle JM, Von T, Roberts
TM, Lin NU, Krop IE, Winer EP and Zhao JJ: PI3K-p110α mediates
resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast
cancers. Oncogene. 35:3607–3612. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Mezni E, Vicier C, Guerin M, Sabatier R,
Bertucci F and Gonçalves A: New therapeutics in HER2-positive
advanced breast cancer: Towards a change in clinical practices?
Cancers (Basel). 12:15732020. View Article : Google Scholar
|
|
69
|
André F, O'Regan R, Ozguroglu M, Toi M, Xu
B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, et al:
Everolimus for women with trastuzumab-resistant, HER2-positive,
advanced breast cancer (BOLERO-3): A randomised, double-blind,
placebo-controlled phase 3 trial. Lancet Oncol. 15:580–591. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hurvitz SA, André F, Jiang Z, Shao Z, Mano
MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, et al:
Combination of everolimus with trastuzumab plus paclitaxel as
first-line treatment for patients with HER2-positive advanced
breast cancer (BOLERO-1): A phase 3, randomised, double-blind,
multicentre trial. Lancet Oncol. 16:816–829. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
André F, Hurvitz S, Fasolo A, Tseng LM,
Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H, et al:
Molecular alterations and everolimus efficacy in human epidermal
growth factor receptor 2-overexpressing metastatic breast cancers:
Combined exploratory biomarker analysis From BOLERO-1 and BOLERO-3.
J Clin Oncol. 34:2115–2124. 2016.Erratum in: J Clin Oncol 37: 357,
2019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Guerin M, Rezai K, Isambert N, Campone M,
Autret A, Pakradouni J, Provansal M, Camerlo J, Sabatier R,
Bertucci F, et al: PIKHER2: A phase IB study evaluating buparlisib
in combination with lapatinib in trastuzumab-resistant
HER2-positive advanced breast cancer. Eur J Cancer. 86:28–36. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Jain S, Shah AN, Santa-Maria CA,
Siziopikou K, Rademaker A, Helenowski I, Cristofanilli M and
Gradishar WJ: Phase I study of alpelisib (BYL-719) and trastuzumab
emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC)
after trastuzumab and taxane therapy. Breast Cancer Res Treat.
171:371–381. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Viale G, Morganti S, Ferraro E, Zagami P,
Marra A and Curigliano G: What therapies are on the horizon for
HER2 positive breast cancer? Expert Rev Anticancer Ther.
19:811–822. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Emens LA, Esteva F, Beresford M, Saura C,
De Laurentiis M, Kim SB, Im SA, Patre M, Wang Y, Mani A, et al:
Results from KATE2, a randomized phase 2 study of atezolizumab
(atezo)+trastuzumab emtasine (T-DM1) vs placebo (pbo)+T-DM1 in
previously treated HER2+ advanced breast cancer (BC). Cancer Res.
79 (Suppl 4):Abstract nr PD3-01. 2019.
|
|
76
|
Emens L, Esteva F, Beresford M, Saura C,
De Laurentiis M, Kim SB, Im SA, Wang Y, Mani A, Shah J, et al:
Overall survival (OS) in KATE2, a phase 2 study of programmed death
ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab
emtasine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+
advanced breast cancer (BC). Ann Oncol. 30 (Suppl 5):v104–v142.
2019. View Article : Google Scholar
|
|
77
|
Loi S, Giobbie-Hurder A, Gombos A,
Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi
H, Jerusalem G, et al International Breast Cancer Study Group and
the Breast International Group, : Pembrolizumab plus trastuzumab in
trastuzumab-resistant, advanced, HER2-positive breast cancer
(PANACEA): A single-arm, multicentre, phase 1b-2 trial. Lancet
Oncol. 20:371–382. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Ayoub NM, Al-Shami KM and Yaghan RJ:
Immunotherapy for HER2-positive breast cancer: Recent advances and
combination therapeutic approaches. Breast Cancer (Dove Med Press).
11:53–69. 2019.PubMed/NCBI
|
